Inovio Pharmaceuticals' Published Universal Flu Vaccine Data Demonstrates Protective Responses Against All Major, Lethal H1N1...
January 22 2018 - 8:00AM
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that
Inovio’s synthetic vaccine approach using a collection of synthetic
DNA antigens generated broad protective antibody responses against
all major deadly strains of H1 influenza viruses from the last 100
years including the virus that caused “Spanish Flu” in 1918 in
multiple animal models including mice, guinea pigs and non-human
primates.
The flu vaccine also affords 100% protection
against lethal challenge in the gold standard ferret model,
demonstrating the functionality of such broad protective immune
responses. Preclinical flu vaccine study results were detailed in a
paper published in the journal Vaccine entitled, “Broad
cross-protective anti-hemagglutination responses elicited by
influenza microconsensus DNA vaccine,” by Inovio scientists and its
collaborators.
A broadly protective flu vaccine would be of
great value given how rapidly a pandemic strain could emerge.
According to a recent editorial in Science Magazine: “….influenza
viruses are moving targets, and a pandemic virus could nevertheless
emerge with as little warning in 2018 as in 1918. As evidenced by
this current flu season, influenza viruses can rapidly acquire
mutations that evade our most recent vaccine formulations. A
universal, broadly protective influenza vaccine for seasonal
epidemics – a goal of intense research efforts -- would improve our
preparedness for subsequent pandemics.”
Dr. Laurent Humeau, Inovio's Sr. VP, Research
and Development, said, "Funded by a grant from the NIH, this
published work demonstrates that Inovio’s ASPIRE™ (Antigen SPecific
Immune REsponses) technology platform could produce a universal flu
vaccine that can span seasonal vaccine changes allowing for
continued immune protection. We are proud to advance Inovio
technology and contribute to advance cutting edge technology for
the important global health treats. These studies also showcase the
latest CELLECTRA® intradermal (skin) delivery system to facilitate
optimal antigen production and generation of superior immune
responses in animal models.”
Globally influenza remains an important pathogen
contributing to significant deaths and illness each year. The CDC
estimates that 56,000 Americans died from influenza-associated
deaths in the United States during 2012-2013 flu season. Even with
the seasonal flu vaccines generating $3.8 billion in global revenue
(WHO estimate), the currently approved seasonal influenza vaccines
provide protection against only the three or four strains included
in their specific formulations and are therefore incapable of
addressing the inevitable and frequent shift and drift of influenza
viral strains that can occur from season to season. Scientists have
long been searching for an influenza vaccine designed to be broadly
protective against multiple, unmatched influenza virus
strains.
In this published study, Inovio report on a
synthetic micro-consensus approach that relies on a small
collection of 4 synthetic H1HA DNA antigens which delivered in a
single dose generated broadly protective antibody immune responses
against several major deadly strains of H1N1 flu viruses from the
last 100 years including the strain that caused the 1918 Spanish
Flu (which killed over 40 million people) in mice, guinea pigs and
non-human primates. The vaccine also protected 100% of immunized
ferrets from a lethal virus challenge. These results are
encouraging that a limited easy-to-formulate collection of
micro-consensus antigens can be developed which can span seasonal
vaccine changes allowing for continued immune protection. All
of these protective immune responses were generated using Inovio’s
skin delivery system for vaccines. Perhaps most importantly, this
novel strategy could also be used to develop broadly protective
vaccines against other infectious agents like dengue, RSV and
HIV.
About Inovio Pharmaceuticals,
Inc.
Inovio is taking immunotherapy to the next level
in the fight against cancer and infectious diseases. We are the
only immunotherapy company that has reported generating T cells in
vivo in high quantity that are fully functional and whose killing
capacity correlates with relevant clinical outcomes with a
favorable safety profile. Furthermore, the ASPIRE™ technology
generates potent antibody immunity as well allowing for all arms of
the immune system to engage pathogens as well as to attack cancers.
With an expanding portfolio of immune therapies, the company
is advancing a growing preclinical and clinical stage product
pipeline. Partners and collaborators include MedImmune, Regeneron,
Genentech, The Wistar Institute, University of Pennsylvania, The
Parker Institute for Cancer Immunotherapy, DARPA, GeneOne Life
Science, Plumbline Life Sciences, ApolloBio Corporation, Drexel
University, NIH, HIV Vaccines Trial Network, National Cancer
Institute, U.S. Military HIV Research Program, and Laval
University. For more information, visit www.inovio.com.
This press release contains certain
forward-looking statements relating to our business, including our
plans to develop electroporation-based drug and gene delivery
technologies and DNA vaccines, our expectations regarding our
research and development programs, including the planned initiation
and conduct of clinical trials and the availability and timing of
data from those trials, and the sufficiency of our capital
resources. Actual events or results may differ from the
expectations set forth herein as a result of a number of factors,
including uncertainties inherent in pre-clinical studies, clinical
trials and product development programs, the availability of
funding to support continuing research and studies in an effort to
prove safety and efficacy of electroporation technology as a
delivery mechanism or develop viable DNA vaccines, our ability to
support our pipeline of SynCon® active immunotherapy and vaccine
products, the ability of our collaborators to attain development
and commercial milestones for products we license and product sales
that will enable us to receive future payments and royalties, the
adequacy of our capital resources, the availability or potential
availability of alternative therapies or treatments for the
conditions targeted by the company or its collaborators, including
alternatives that may be more efficacious or cost effective than
any therapy or treatment that the company and its collaborators
hope to develop, issues involving product liability, issues
involving patents and whether they or licenses to them will provide
the company with meaningful protection from others using the
covered technologies, whether such proprietary rights are
enforceable or defensible or infringe or allegedly infringe on
rights of others or can withstand claims of invalidity and whether
the company can finance or devote other significant resources that
may be necessary to prosecute, protect or defend them, the level of
corporate expenditures, assessments of the company's technology by
potential corporate or other partners or collaborators, capital
market conditions, the impact of government healthcare proposals
and other factors set forth in our Annual Report on Form 10-K for
the year ended December 31, 2016, our Form 10-Q for the
period ended September 30, 2017, and other regulatory filings we
make from time to time. There can be no assurance that any product
candidate in Inovio's pipeline will be successfully developed,
manufactured or commercialized, that final results of clinical
trials will be supportive of regulatory approvals required to
market licensed products, or that any of the forward-looking
information provided herein will be proven accurate.
Forward-looking statements speak only as of the date of this
release, and Inovio undertakes no obligation to update or revise
these statements, except as may be required by law.
CONTACTS:
Investors: Ben
Matone, Inovio, 484-362-0076, ben.matone@inovio.comMedia:
Jeff Richardson, Inovio, 267-440-4211, jrichardson@inovio.com
Inovio Pharmaceuticals (NASDAQ:INO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Inovio Pharmaceuticals (NASDAQ:INO)
Historical Stock Chart
From Apr 2023 to Apr 2024